12.24

4.23% -0.54

Biomea Fusion Inc (BMEA)

Overview News Price History Option Chain Financials Why BMEA Down? Discussions Forecast

Biomea Fusion Inc stock is currently priced at $12.24, with a 24-hour trading volume of 531.80K. It has seen a -4.23% decreased in the last 24 hours and a +6.43% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $12.96 pivot point. If it approaches the $12.21 support level, significant changes may occur.

Previous Close:

$12.78

Open:

$12.85

24h Volume:

531.80K

Market Cap:

$439.96M

Revenue:

Net Income/Loss:

$-117.26M

P/E Ratio:

-3.6867

EPS:

-3.32

Net Cash Flow:

$-99.96M

1W Performance:

+14.93%

1M Performance:

+6.43%

6M Performance:

+17.69%

1Y Performance:

-62.79%

1D Range:

$12.17

$12.85

52W Range:

$8.125

$43.69

Biomea Fusion Inc Stock (BMEA) Company Profile

Name

Biomea Fusion Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650 980 9099

Address

Chamberlain Building, 726 Main Street, Redwood City

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BMEA's Discussions on Twitter

Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-24	Initiated	Truist	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight
Mar-29-23	Reiterated	Oppenheimer	Outperform
Mar-28-23	Reiterated	H.C. Wainwright	Buy
Feb-24-23	Initiated	Citigroup	Buy
Jun-02-22	Resumed	H.C. Wainwright	Buy
Jan-12-22	Initiated	H.C. Wainwright	Buy
Dec-17-21	Initiated	Oppenheimer	Outperform
May-11-21	Initiated	JP Morgan	Overweight
May-11-21	Initiated	Jefferies	Buy
May-11-21	Initiated	Piper Sandler	Overweight

View All

Biomea Fusion Inc Stock (BMEA) Latest News

Brokerages Set Biomea Fusion, Inc. (NASDAQ:BMEA) Price Target at $53.25 - MarketBeat

MarketBeat

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Defense World

Brokerages Set Biomea Fusion, Inc. (NASDAQ:BMEA) Price Target at $53.25 - MarketBeat

MarketBeat

Biomea Fusion Inc Stock (BMEA) Financials Data

Biomea Fusion Inc (BMEA) Net Income 2024

BMEA net income (TTM) was -$117.25 million for the quarter ending December 31, 2023, a -43.29% decrease year-over-year.

Biomea Fusion Inc (BMEA) Cash Flow 2024

BMEA recorded a free cash flow (TTM) of -$99.96 million for the quarter ending December 31, 2023, a -57.55% decrease year-over-year.

Biomea Fusion Inc (BMEA) Earnings per Share 2024

BMEA earnings per share (TTM) was -$3.46 for the quarter ending December 31, 2023, a -24.01% decline year-over-year.

Biomea Fusion Inc Stock (BMEA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
A2A Pharmaceuticals, Inc.	10% Owner	May 31 '23	Sale	33.81	75,000	2,535,750	3,550,000

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is headquartered in Redwood City, California.